CBO provides additional information about how the certification provision in the INSULIN Act would affect the prices for insulin and the federal budget.
This letter provides additional information that Senator Susan Collins and Senator Jeanne Shaheen requested about how the certification provision in the Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act would affect the prices for insulin and the federal budget. In brief, the Congressional Budget Office finds that the provision would, on average, reduce list prices and cost sharing for insulin products while increasing net prices for insulin products, premiums for health insurance, and federal spending.
